|Articles|November 12, 2021
Daily OTC Pearl: Melatonin
Author(s)Saro Arakelians, PharmD
Natural melatonin sends messages to the receptor agonist in the brain and other areas of the body to help control the sleep and wake cycles.
Advertisement
OTC/Lifestyle Pearl of the Day: Melatonin
Indication: Melatonin is the natural hormone the body secretes that helps to maintain the wake-sleep cycle (also called biological clock).
Insight:
Melatonin is also made synthetically and available without a prescription as an OTC dietary supplement in the United States.- The wake-sleep cycle is the process of sleep and wakefulness. In humans, the average is 8 hours of nighttime sleep and 16 hours of daytime activity.
- Mechanism of action: Natural melatonin is a highly lipid soluble hormone produced in the pineal gland in the brain. It sends messages to the receptor agonist in the brain and other areas of the body to help control the sleep and wake cycles.
- Effective starting doses of melatonin for
jet lag range from 0.3 to 0.5 mg. - One milligram tablet can be cut in half to achieve a 0.5 mg dose of melatonin if smaller doses are not available for purchase.
- Adverse effects may include bedwetting, headache, dizziness, nausea, and diarrhea.
- Dosages available are at 0.125 mg, 0.3 mg, 0.5 mg, 2 mg controlled release, 3 mg, 5 mg, 10 to 50 mg.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5